BUCHANAN INGERSOLL & ROONEY PC for AIM IMMUNOTECH INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 10, 2022 | $40,000 | Replaced |
| 4th Quarter - Amendment | Jan 10, 2022 | $40,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. FY 2022 Appropriations for Defense Department, and National Institutes of Health (NIH)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KYLE A DARBY New | — |
| MICHAEL P STRAZZELLA | — |
| JAMES C WILTRAUT | — |
Pharmacy PHA
Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. FY 2022 Appropriations for Defense Department, and National Institutes of Health (NIH)
| Lobbyist | Covered position, as disclosed |
|---|---|
| KYLE A DARBY New | — |
| MICHAEL P STRAZZELLA | — |
| JAMES C WILTRAUT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.